[Adjuvant therapy after treatment of hepatocellular carcinoma].
Kasai
Kazuhiro
K
Department of Gastroenterology and Hepatology, Iwate Medical University.
Kuroda
Hidekatsu
H
Suzuki
Kazuyuki
K
D000597:Amino Acids, Branched-Chain / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control / Q000628:therapy*; D003920:Diabetes Mellitus; D006801:Humans; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000517:prevention & control / Q000628:therapy*; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009765:Obesity; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014212:Tretinoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use
D000597:Amino Acids, Branched-Chain; D000806:Angiotensin-Converting Enzyme Inhibitors; D000970:Antineoplastic Agents; D014812:Vitamin K; D019259:Lamivudine; D014212:Tretinoin; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid; D007372:Interferons